Psychiatria Danubina · 2025
The effect of olanzapine on IGF-1/IGF-1R and volumes in the prefrontal cortex and hippocampus in a model of bipolar mania.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Çakmak Eser, Tunçel Özgür Korhan, Önger Mehmet Emin
Аннотация
BACKGROUND: The aim of the study is to determine the changes in insulin-like growth factor 1 (IGF-1) and its receptor (IGF-1R) in the emergence of bipolar disorder and its treatment with olanzapine.
SUBJECTS AND METHODS: Of all 48 adult male albino wistar rats, the control group (n=12) saline, ketamine group (n=12) ketamine (25mg/kg), olanzapine group (n=12) olanzapine (2mg/kg), ketamine+olanzapine group (n=12) ketamine (25 mg/kg) was administered once a day/14 days. Olanzapine (2mg/kg) was administered once a day to the ketamine+olanzapine group between 8 and 14 days. Volume, IGF-1, and IGF-1R gene expression and protein levels were measured in the prefrontal cortex and hippocampus.
RESULTS: In the prefrontal cortex, there was a decrease in volume, IGF-1R gene expression, and protein levels in the ketamine group, an increase in IGF-1 gene expression and protein levels in the olanzapine group; an increase in IGF-1R gene expression, IGF-1, and IGF-1R protein levels in the ketamine+olanzapine group. In hippocampus, there was a decrease in volume, IGF-1 gene expression and protein levels in ketamine group, a decrease in volume and IGF-1 protein levels, increase in IGF-1R gene expression and protein levels in olanzapine group; a decrease in volume, IGF-1 protein levels and IGF-1R gene expression and protein levels in ketamine+olanzapine group.
CONCLUSIONS: One of the underlying causes of bipolar disorder may be changes in the IGF-1 and IGF-1R regions in the prefrontal cortex and hippocampus. Olanzapine has a neuroprotective effect by increasing IGF-1 and IGF-1R levels in the prefrontal cortex, and a neurodegenerative effect by decreasing IGF-1 and IGF-1R levels in the hippocampus.
SUBJECTS AND METHODS: Of all 48 adult male albino wistar rats, the control group (n=12) saline, ketamine group (n=12) ketamine (25mg/kg), olanzapine group (n=12) olanzapine (2mg/kg), ketamine+olanzapine group (n=12) ketamine (25 mg/kg) was administered once a day/14 days. Olanzapine (2mg/kg) was administered once a day to the ketamine+olanzapine group between 8 and 14 days. Volume, IGF-1, and IGF-1R gene expression and protein levels were measured in the prefrontal cortex and hippocampus.
RESULTS: In the prefrontal cortex, there was a decrease in volume, IGF-1R gene expression, and protein levels in the ketamine group, an increase in IGF-1 gene expression and protein levels in the olanzapine group; an increase in IGF-1R gene expression, IGF-1, and IGF-1R protein levels in the ketamine+olanzapine group. In hippocampus, there was a decrease in volume, IGF-1 gene expression and protein levels in ketamine group, a decrease in volume and IGF-1 protein levels, increase in IGF-1R gene expression and protein levels in olanzapine group; a decrease in volume, IGF-1 protein levels and IGF-1R gene expression and protein levels in ketamine+olanzapine group.
CONCLUSIONS: One of the underlying causes of bipolar disorder may be changes in the IGF-1 and IGF-1R regions in the prefrontal cortex and hippocampus. Olanzapine has a neuroprotective effect by increasing IGF-1 and IGF-1R levels in the prefrontal cortex, and a neurodegenerative effect by decreasing IGF-1 and IGF-1R levels in the hippocampus.